PD-1/PD-L1 and CTLA-4 blockade have given impressive clinical results in various tumor types.41 In TNBC, one of the most encouraging immunotherapies is the anti-PD-1/PD-L1 monotherapy. The gene discussed is CTLA4; the disease is neoplasm.